Senti Biosciences Inc
SNTI
NASDAQ
Biotechnology
$0.45
USD
+0.07 (+16.93%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $11.96M
Volume 597.6K
Revenue
$38,000
TTM
— YoY
Gross Margin
100%
TTM
— YoY
Net Income
$-51.55M
TTM
+5.9%
YoY
Operating Cash Flow
$-36.88M
TTM
+15.7%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 7.1 | 6.8 | 6.4 | 5.8 | 6.2 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 5.1 | -6.9 |
Total Operating Expenses | 16.4 | 16.8 | 16.9 | 18.7 | 4.6 |
Operating Income | -16.4 | -16.8 | -16.9 | -18.6 | -4.6 |
EBITDA | -15.5 | -15.9 | -16.0 | -12.7 | -10.8 |
Other Income / Expense | 1.9 | 1.8 | -1.3 | 4.1 | 0.3 |
Total Other Income / Expense | 2.3 | 2.1 | -1.2 | 4.2 | 0.4 |
Income Before Income Taxes | -14.1 | -14.7 | -18.1 | -14.5 | -4.2 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -14.1 | -14.7 | -18.1 | -14.5 | -4.2 |
Consolidated Net Income / Loss | -14.1 | -14.7 | -18.1 | -14.5 | -4.2 |
Net Income Attributable to Common Shareholders | -14.1 | -14.7 | -18.1 | -14.5 | -4.2 |
Basic EPS | -$1.41 | -$0.56 | -$0.69 | -$0.52 | -$0.14 |
Diluted EPS | -$1.41 | -$0.56 | -$0.69 | -$0.52 | -$0.14 |
Basic Shares Outstanding | 10.0M | 26.1M | 26.2M | 27.6M | 31.0M |
Diluted Shares Outstanding | 10.0M | 26.1M | 26.2M | 27.6M | 31.0M |